OMED

OncoMed Pharmaceuticals, Inc.

OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

83 hedge funds and large institutions have $107M invested in OncoMed Pharmaceuticals, Inc. in 2016 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 34 increasing their positions, 20 reducing their positions, and 10 closing their positions.

2019 Q3 2019 Q2 2019 Q1 2018 Q4 2018 Q3 2018 Q2 2018 Q1 2017 Q4 2017 Q3 2017 Q2 2017 Q1 2016 Q4 2016 Q3 2016 Q2 2016 Q1 2015 Q4 2015 Q3 2015 Q2 2015 Q1 2014 Q4 2014 Q3 2014 Q2 2014 Q1 2013 Q4 2013 Q3

Holders

Holders Change

–

Holders Change %

% of All Funds

2.22%

Holding in Top 10

Holding in Top 10 Change

-2

Holding in Top 10 Change %

-66.67%

% of All Funds

0.03%

New

Increased

Reduced

Closed

Calls

$2.25M

Puts

$1.05M

Net Calls

+$1.21M

Net Calls Change

+$174K

Top Buyers

1	BI 1 BVF Inc San Francisco, California	$13.5M
2	2 First Eagle Investment Management New York	$1.87M
3	3 Alyeska Investment Group Chicago, Illinois	$3.29M
4	4 Vanguard Group Malvern, Pennsylvania	$6.08M
5	BIM 5 Bogle Investment Management Newton Lower Falls, Massachusetts	$1.13M

Top Sellers

1	VAM 1 Visium Asset Management New York	$0
2	2 Balyasny Asset Management Chicago, Illinois	$0
3	3 Wells Fargo San Francisco, California	$155K
4	4 Fidelity Investments Boston, Massachusetts	$9.21M
5	5 Morgan Stanley New York	$214K

#	Name	Market Value	Shares	Shares Change	Shares Change %
26	NSEDCP 26 NJ State Employees Deferred Compensation Plan Trenton, New Jersey	$784K	70,000	–	–
27	BC 27 Birchview Capital Burlington, Vermont	$715K	70,689	+12,000	+20%
28	QI 28 QS Investors New York	$650K	64,307	–	–
29	BIM 29 BlackRock Investment Management Wilmington, Delaware	$598K	59,165	+10	+0%
30	30 Goldman Sachs New York	$572K	56,611	+42,274	+295%
31	HCM 31 Hodges Capital Management Dallas, Texas	$556K	55,000	+20,000	+57%
32	TCIM 32 TIAA CREF Investment Management New York	$542K	53,603	-36,836	-41%
33	33 Millennium Management New York	$479K	47,356	+47,356	New
34	34 JPMorgan Chase & Co New York	$447K	44,242	-94,936	-68%
35	35 Charles Schwab San Francisco, California	$427K	42,233	+714	+2%
36	36 Deutsche Bank Frankfurt Am Main Ge, Germany	$406K	40,244	+10,089	+33%
37	PI 37 Putnam Investments Boston, Massachusetts	$388K	38,314	+244	+0.6%
38	38 California State Teachers Retirement System (CalSTRS) West Sacramento, California	$362K	35,807	+4,418	+14%
39	AA 39 ALPS Advisors Denver, Colorado	$342K	33,861	-5,802	-15%
40	NFA 40 Nationwide Fund Advisors Columbus, Ohio	$339K	33,569	-1,115	-3%
41	TAM 41 Tocqueville Asset Management New York	$315K	31,200	-26,050	-46%
42	GT 42 Glenmede Trust Philadelphia, Pennsylvania	$290K	28,700	–	–
43	TA 43 Teachers Advisors New York	$278K	27,462	+3,165	+13%
44	44 Handelsbanken Fonder Stockholm, Sweden	$253K	25,000	+25,000	New
45	PP 45 PDT Partners New York	$250K	24,750	+8,050	+48%
46	TC 46 TFS Capital West Chester, Pennsylvania	$250K	24,726	+24,726	New
47	47 ProShare Advisors Bethesda, Maryland	$246K	24,357	-2,320	-9%
48	PCM 48 Piermont Capital Management St. Louis, Missouri	$221K	21,895	+835	+4%
49	49 Morgan Stanley New York	$214K	21,140	-129,122	-86%
50	50 New York State Common Retirement Fund Albany, New York	$178K	17,600	–	–

OncoMed Pharmaceuticals, Inc. OMED

Top Buyers

Top Sellers

OncoMed Pharmaceuticals, Inc.

OMED